CA
NZ
UK
AU
IND
US
Few micro-cap biotechs get a second act as clean as the one Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) has written. Less than three years after Nasdaq removed it from the exchange, the shares trade on theNasdaq Capital Marketagain, theBalance Sheetholds about $62 million, and the lead …
FibroBiologics, Inc. (NASDAQ:FBLG) is a Houston-based clinical-stage biotechnology company building therapies from fibroblasts, the connective-tissue cells that make collagen and the other proteins the body uses to rebuild damaged tissue. Listed since January 2024, it spent most of its short public life as a …
For years, PDS Biotechnology Corporation (NASDAQ:PDSB) has been defined by one asset: Versamune HPV, or PDS0101, an investigational immunotherapy for HPV16-positive head and neck cancer. On 11 August 2026 the Princeton, New Jersey company told shareholders it would stop funding that programme's pivotal study …
Soligenix, Inc. (NASDAQ:SNGX) has spent 2026 rebuilding itsInvestmentcase from the ground up. For years the Princeton, New Jersey biotech pointed investors to HyBryte, a synthetic hypericin activated by visible light, in cutaneous T-cell lymphoma, a rare cancer of white blood cells that appears as …
AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) has spent two years fighting on two fronts: keeping its lead drug Ampligen moving through the clinic, and keeping its shares on a national exchange. As of mid-August 2026, the second fight is over.
Azitra, Inc. (NYSEAMERICAN:AZTR) is built on an unusual idea: engineer Staphylococcus epidermidis, a bacterium that already lives on human skin, so it makes useful proteins where they are needed. For most of its public life it sold that platform as a rare-disease dermatology story.
Curis, Inc. (NASDAQ:CRIS), the Lexington, Massachusetts oncology developer behind emavusertib, has packed a lot into 2026: a January private placement, a 1-for-20Reverse Stock Splitin July, an encouraging brain-lymphoma data update, and now a small, tightly pricedEquityraise.
Femasys Inc. (NASDAQ:FEMY) has spent 2026 running two races at once: proving its women's health devices can sell, and funding the clinical trial that could unlock its biggest market. In early August, the Suwanee, Georgia company made decisive progress on the second front.
HCW Biologics Inc. (NASDAQ:HCWB) has spent 2026 doing two hard things at once: defending its Nasdaq listing and funding its laboratories. By mid-August the Miramar, Florida biotech had made progress on both.
BioVie Inc. (NASDAQ:BIVI) has argued for years that chronic inflammation in the brain is a treatable driver of neurodegenerative disease, not merely a by-product of it. On 6 August 2026 the Carson City, Nevada clinical-stage company produced its cleanest evidence yet: a randomised, placebo-controlled …
Please wait processing your request...